Oxytocin as an Additive Intervention to Conventional Testosterone and Erection Medication for Men

You are currently viewing Oxytocin as an Additive Intervention to Conventional Testosterone and Erection Medication for Men

Chief Medical Officer, Dr. Michael Krychman, MDCM of Revibe Men’s Health recently completed an Oxytocin responder analysis for patients who have used Oxytocin in conjunction with their testosterone replacement therapy or erectile dysfunction treatment to determine if the use of Oxytocin changed or improved performance outcomes in the test subjects.

Oxytocin (OT), a peptide hormone, is known to be involved in social interaction and the pleasure we derive from it is produced from the posterior pituitary. This neurotransmitter, or brain chemical has a potential role in love, female reproductive functions, and social bonding. OT is released by both males and females, during skin to skin contact sexual arousal and orgasm/ejaculation (1,2). OT effects on the brain are dependent on its interactions with sex homes such as estrogen, progesterone, testosterone, and corticosterone. Oxytocin levels are also implicated in the male sexual response. Oxytocin effects may include: decrease social anxiety, increased pair bonding, intimacy and closeness enhance sexual receptivity, enhance perineal contractility, enhances pair bonding, nurturing, trust “cuddle hormone, increased intensity of orgasm in men and women, decreased time to orgasmic release, increased pleasurable sensations and increased sexual desire and lubrication Revibe Men’s Health is a network of 10 national men’s health centers that focuses on general health, weight loss and maintenance, hair restoration and sexual health and wellness. Oxytocin troches have been used as an off label investigational compounded medication as an adjunctive therapy for men’s sexual health. We report here the preliminary responder analysis results of a random retrospective survey on users of this medication.

A random sample of men from 5 centers ( Hawaii, Washington, Portland, Salt Lake City and Tulsa) who tried compounded oxytocin troches were anonymously surveyed. The participants were uncompensated. Doses of Sublingual oxytocin were to be titrate up from 25 IU for optimization, but not to exceed 100 IU.

Almost 60% of participants were considered responders. Mean age of the participants was 43 and the age range was 22-77. Eighty-six percent of the participants used between 50 IU and 100 IU and 50% were on TRT replacement whereas 57% were on Erectile medications. Only 21% were on both ED medications and TRT replacement.

Some Important top line results include:
86% of responders reported enhanced intimacy and connection with their partners
93% of users planned to continue the medication
86% noted increased overall pleasure and sexual satisfaction
86% reported improved overall quality of their orgasm

100% would recommend the product to their friends.

There were no adverse events reported.

Responders reported positive feedback which included: longer lasting before orgasmic release, increased nipple sensation, improved control with premature ejaculation, improved feelings during climax and increased ejaculate volume.

Dr. Krychman reiterated that, “It is exciting to report this preliminary result. Compounded oxytocin troches appear to be a helpful addition to a preexisting treatment paradigm for men with erectile difficulties or for those on testosterone replacement. While this is a preliminary report with quite small numbers, the study shows excellent promise and further larger randomized clinical trials are indeed warranted.”

Revibe Men’s Health remains dedicated to cutting edge treatment options for mens sexual health and wellness, and will continue their dedicated research efforts.

References

  1. Navneet Magon, et al. The orgasmic history of oxytocin: Love, lust, and labor. Indian Journal of Endocrinology and Metabolism / 2011 / Vol 15 Supplement 3
  2. Ishak et al Oxytocin role in enhancing well-being: A literature review. Journal of Affective Disorders 130 (2011) 1–9